PURPOSE: To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cervical cancer. METHODS AND MATERIALS: Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent. Severe late toxicity was defined as grade≥3 vaginal, urologic, or gastrointestinal toxicity or any pelvic fracture, using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE), occurring ≥6 months from treatment completion and predating any salvage therapy. Severe late toxicity rates were compared after adjusting for pertinent covariates. RESULTS: At 3 years, probability of vaginal severe late toxicity was 20.2% for radiotherapy alone and 35.1% for concomitant chemoradiotherapy (P=.026). At 3 years, probability of skeletal severe late toxicity was 1.6% for radiotherapy alone and 7.5% for concomitant chemoradiotherapy (P=.010). After adjustment for case mix, concomitant chemoradiotherapy was associated with higher vaginal (hazard ratio [HR] 3.0, 95% confidence interval [CI], 1.7-5.2, P<.001), and skeletal (HR 7.0, 95% CI 1.4-34.1, P=.016) severe late toxicity. Compared to high dilator compliance, moderate (HR 3.6, 95% CI 2.0-6.5, P<.001) and poor (HR 8.5, 95% CI 4.3-16.9, P<.001) dilator compliance was associated with higher vaginal severe late toxicity. Age>50 was associated with higher vaginal (HR 1.8, 95% CI 1.1-3.0, P=.013) and skeletal (HR 5.7, 95% CI 1.2-27.0, P=.028) severe late toxicity. Concomitant chemoradiotherapy was not associated with higher gastrointestinal (P=.886) or urologic (unadjusted, P=.053; adjusted, P=.063) severe late toxicity. CONCLUSION: Compared to radiotherapy alone, concomitant chemoradiotherapy is associated with higher rates of severe vaginal and skeletal late toxicities. Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities.
PURPOSE: To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cervical cancer. METHODS AND MATERIALS: Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent. Severe late toxicity was defined as grade≥3 vaginal, urologic, or gastrointestinal toxicity or any pelvic fracture, using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE), occurring ≥6 months from treatment completion and predating any salvage therapy. Severe late toxicity rates were compared after adjusting for pertinent covariates. RESULTS: At 3 years, probability of vaginal severe late toxicity was 20.2% for radiotherapy alone and 35.1% for concomitant chemoradiotherapy (P=.026). At 3 years, probability of skeletal severe late toxicity was 1.6% for radiotherapy alone and 7.5% for concomitant chemoradiotherapy (P=.010). After adjustment for case mix, concomitant chemoradiotherapy was associated with higher vaginal (hazard ratio [HR] 3.0, 95% confidence interval [CI], 1.7-5.2, P<.001), and skeletal (HR 7.0, 95% CI 1.4-34.1, P=.016) severe late toxicity. Compared to high dilator compliance, moderate (HR 3.6, 95% CI 2.0-6.5, P<.001) and poor (HR 8.5, 95% CI 4.3-16.9, P<.001) dilator compliance was associated with higher vaginal severe late toxicity. Age>50 was associated with higher vaginal (HR 1.8, 95% CI 1.1-3.0, P=.013) and skeletal (HR 5.7, 95% CI 1.2-27.0, P=.028) severe late toxicity. Concomitant chemoradiotherapy was not associated with higher gastrointestinal (P=.886) or urologic (unadjusted, P=.053; adjusted, P=.063) severe late toxicity. CONCLUSION: Compared to radiotherapy alone, concomitant chemoradiotherapy is associated with higher rates of severe vaginal and skeletal late toxicities. Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities.
Authors: B R Thomadsen; S Shahabi; J A Stitt; D A Buchler; J F Fowler; B R Paliwal; T J Kinsella Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: R Pearcey; M Brundage; P Drouin; J Jeffrey; D Johnston; H Lukka; G MacLean; L Souhami; G Stuart; D Tu Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Kathleen M Schmeler; Anuja Jhingran; Revathy B Iyer; Charlotte C Sun; Patricia J Eifel; Pamela T Soliman; Pedro T Ramirez; Michael Frumovitz; Diane C Bodurka; Anil K Sood Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: J A Stitt; J F Fowler; B R Thomadsen; D A Buchler; B P Paliwal; T J Kinsella Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Dongryul Oh; Seung Jae Huh; Heerim Nam; Won Park; Youngyih Han; Do Hoon Lim; Yong Chan Ahn; Jeong Won Lee; Byoung Gie Kim; Duk Soo Bae; Je Ho Lee Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-24 Impact factor: 7.038
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: J M Herter; M Kiljan; S Kunze; M Reinscheid; O Ibruli; J Cai; L Niu; I Heßelmann; M Trommer; G S Herter-Sprie; C Köhler; S Marnitz Journal: Strahlenther Onkol Date: 2022-10-17 Impact factor: 4.033
Authors: Milan Vosmik; Jan Laco; Igor Sirak; Martin Beranek; Eva Hovorkova; Hana Vosmikova; Monika Drastikova; Miroslav Hodek; Zdenek Zoul; Karel Odrazka; Jiri Petera Journal: Pathol Oncol Res Date: 2013-08-03 Impact factor: 3.201
Authors: C Pisani; L Deantonio; D Surico; M Brambilla; A Galla; E Ferrara; L Masini; G Gambaro; N Surico; M Krengli Journal: Clin Transl Oncol Date: 2015-11-25 Impact factor: 3.405
Authors: John M Stahl; Jack M Qian; Christopher J Tien; David J Carlson; Zhe Chen; Elena S Ratner; Henry S Park; Shari Damast Journal: Support Care Cancer Date: 2018-09-05 Impact factor: 3.603
Authors: Yanlan Chai; Tao Wang; Juan Wang; Yunyi Yang; Ying Gao; Jiyong Gao; Shangfeng Gao; Yueling Wang; Xi Zhou; Zi Liu Journal: BMC Cancer Date: 2014-02-04 Impact factor: 4.430
Authors: Leila T Tchelebi; Emma Batchelder; Ming Wang; Eric J Lehrer; Joseph J Drabick; Navesh Sharma; Mitchell Machtay; Daniel M Trifiletti; Nicholas G Zaorsky Journal: JNCI Cancer Spectr Date: 2021-05-19